Mobile Health Screening ROI: What Donors Get per Dollar

Funders evaluating community health portfolios in Sub-Saharan Africa face a stubborn measurement gap. The proposals arrive with compelling narratives and aspirational reach targets, but the unit economics that would let a donor compare one intervention against another are rarely on the page. Mobile health screening return on investment is now one of the few areas in global health where that gap is closing, because phone-based programs generate cost and reach data automatically as a byproduct of running. For a program officer deciding where the next grant tranche should go, this shift from anecdote to auditable figures changes how capital gets allocated.

"A scaled backbone of community health workers can generate a return of nearly 10 to 1 once averted economic losses and productivity gains are counted." - Investing in Health for Africa, PMNCH/WHO (2017)

That headline ratio is the reason donors keep returning to community-based delivery. The newer question is what happens to it when a smartphone replaces the cold chain of imported equipment, the per-site capital outlay, and the travel costs that historically dominated outreach budgets.

Understanding mobile health screening return on investment

Mobile health screening return on investment is best understood as two linked ratios. The first is the cost per person reached, which captures efficiency of delivery. The second is the cost per outcome, usually expressed as cost per year of life saved or cost per disability-adjusted life year (DALY) averted, which captures whether the reach actually translated into health value. Donors who fund only on cost per person reached tend to overpay for low-yield screening; donors who fund only on cost per outcome tend to starve programs of the volume needed to find the cases worth treating. The strongest portfolios track both.

The evidence base is now specific enough to anchor those ratios. A widely cited evaluation of a mobile HIV screening unit in Cape Town led by researchers at the University of Cape Town reported an intervention cost of roughly 29 to 31 US dollars per result and an incremental cost-effectiveness ratio of about 2,400 US dollars per year of life saved, a figure the authors classified as very cost-effective by World Health Organization thresholds. Compare that against fixed mobile clinic delivery: a cost evaluation of reproductive and primary health care mobile units across two rural South African districts found per-patient costs ranging from roughly 46 to 76 US dollars. The difference is structural. Vehicle-and-staff outreach carries fuel, depreciation, and per-trip overhead that phone-mediated screening does not.

The following table summarizes how the main delivery models compare on the metrics a funder actually underwrites.

Delivery model	Indicative cost per person screened	Capital required per site	Reach ceiling	Data captured automatically
Smartphone-based screening (CHW-led)	Low (sub-10 USD range in pooled estimates)	Minimal; existing handsets	High; limited mainly by CHW time	Yes
Mobile clinic vehicle outreach	46 to 76 USD per patient (rural South Africa)	High; vehicle plus equipment	Moderate; route-bound	Partial
Fixed peripheral clinic	Moderate to high; underused in remote areas	Very high; building plus power	Low for dispersed populations	Partial
Imported point-of-care device campaign	Variable; consumables recur	High; device plus supply chain	Moderate; stock-limited	Rarely

The numbers in any single program will move with disease prevalence, staff wages, and geography. The pattern across them is consistent: removing dedicated hardware and travel from the cost stack is what bends the curve for donor funded health technology.

Where the dollar goes further, and where it does not

Phone-based screening does not dominate on every axis. It concentrates its advantage in specific conditions:

• High-prevalence, high-volume screening where finding cases early avoids expensive late-stage treatment, such as hypertension, anemia, and respiratory distress.
• Dispersed rural populations where the marginal cost of reaching the next village by vehicle is high but the marginal cost of equipping another community health worker with software is near zero.
• Programs that need population-level data for ministries and funders, since digital screening logs reach, referral, and follow-through without a separate monitoring budget.

It is weaker where a definitive diagnosis requires a laboratory confirmation, where connectivity is absent for long stretches, or where the condition being screened is rare enough that the yield per thousand screens cannot justify any program. Honest cost modeling names these boundaries rather than hiding them.

A useful caution comes from the cost literature itself. A 2025 scoping review in PLOS Global Public Health examining community health worker programs for HIV, tuberculosis, and malaria across low- and middle-income countries found cost per beneficiary spanning an enormous range, from about 1.20 US dollars to more than 26,000 US dollars. That spread is not noise. It reflects how much program design, target condition, and scale determine the final ratio. Mobile health screening return on investment is a property of the whole program, not of the technology alone.

Industry Applications

National screening and immunization campaigns

Ministries running supplementary immunization or non-communicable disease screening days can attach contactless vital-signs capture to events that already gather large crowds. The incremental cost is software and training rather than new infrastructure, which is why integration with existing campaigns tends to produce the lowest cost per person reached.

Donor-funded NGO field programs

For NGOs, the reporting burden is often as expensive as the screening itself. Cost effective community screening that logs every encounter digitally collapses monitoring and delivery into one workflow. A program in Uganda referenced in mHealth cost reviews delivered support at roughly 2.35 US dollars per participant against 2.90 US dollars for the non-digital comparison, a margin that compounds across hundreds of thousands of encounters.

Health ministry procurement

Mobile health technology developing countries deploy increasingly favors devices people already own. When the screening tool runs on a standard smartphone, procurement avoids import duties, cold chain, and the recurring consumables that quietly drain device-based budgets after the grant period ends.

Current research and evidence

The cost-effectiveness signal for mHealth Sub-Saharan Africa programs is now reasonably consistent across study types. WHO and PMNCH economic modeling places community health worker investment at a benefit-cost ratio of roughly three to four to one on direct measures, rising toward ten to one when wider productivity gains are included. Clinical cost studies, such as the Cape Town mobile HIV work, put cost per year of life saved well inside very cost-effective territory. Cost evaluations of vehicle-based mobile clinics confirm the higher per-patient floor that phone-based models undercut.

Two evidence gaps remain relevant to funders. First, most published cost-effectiveness work still studies pilots rather than programs at national scale, so the durability of the ratios past the demonstration phase is under-documented. Second, screening cost is only realized as health value when referral and treatment pathways absorb the cases that screening finds. A program that screens cheaply but loses patients before treatment converts a good cost-per-screen into a poor cost-per-outcome. Diligence should follow the patient past the screen.

The Future of mobile health screening return on investment

The trajectory points toward funders underwriting outcomes rather than activities. As digital screening makes reach, referral, and follow-through visible in close to real time, results-based financing becomes practical for programs that previously could not produce verifiable counts. Three developments are likely to define the next phase:

• Standardized cost-per-outcome reporting that lets donors compare programs across countries on a common denominator.
• Tighter coupling of screening data with national health information systems, so community-level findings inform ministry resource allocation.
• A shift in due diligence from input budgets toward audited reach and conversion-to-treatment metrics.

For donors, the practical implication is that the cheapest screening is not automatically the best investment, and the most sophisticated technology is not either. The investment that wins is the one with the lowest defensible cost per outcome at a scale the partner can actually sustain.

Frequently asked questions

How is mobile health screening return on investment measured for donors?

It is measured on two ratios: cost per person screened, which captures delivery efficiency, and cost per outcome such as cost per year of life saved or DALY averted, which captures health value. Strong programs report both, because either one alone can mislead a funding decision.

Is phone-based screening always cheaper than mobile clinics?

Not always, but it usually carries a lower per-patient floor because it removes vehicles, dedicated equipment, and per-trip overhead. Published rural mobile clinic costs of roughly 46 to 76 US dollars per patient sit well above pooled phone-based estimates, though prevalence and geography shift every case.

What is the biggest risk to a strong cost-effectiveness figure?

Weak referral and treatment pathways. Screening that is cheap per person but loses patients before they receive care converts a good cost-per-screen into a poor cost-per-outcome. Donors should fund and monitor the full pathway, not just the screen.

How do digital programs reduce monitoring costs?

Phone-based screening logs each encounter, referral, and follow-up automatically, folding monitoring and evaluation into the delivery workflow rather than requiring a separate budget line for data collection and reporting.

Circadify is building in exactly this space, pairing smartphone-based vital-signs screening deployed with community health workers in Uganda with the cost and reach data funders need to compare investments on a common denominator. Funders and global health partners can review field data and partnership options in the global health section at circadify.com/blog.